Company: DRTSW
Filing Date: 2025-03-12
Form Type: 20-F
Source: 0001213900-25-023187
Chunk: 53

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-03-12
Form: 20-F
Item: Item 3
Chunk 53
---
 our product candidates, we may not be able to realize the benefit of such
transactions if we are unable to successfully integrate them with our existing operations and company culture, which could delay our timelines
or otherwise adversely affect our business. We also cannot be certain that, following a strategic transaction or license, we will achieve
the revenue or specific net income that justifies such transaction. Any delays in entering into new collaborations or strategic partnership
agreements related to our product candidates could delay the development and commercialization of our product candidates in certain geographies
for certain indications, which would harm our business, prospects, financial condition and results of operations.

Risks Related to Our Intellectual Property

If we are unable to obtain and maintain
patent or other intellectual property protection for our Alpha DaRT technology and for any other products or product candidates that we
develop, or if the scope of the patent or other intellectual property protection obtained is not sufficiently broad, our competitors could
develop and commercialize products and technology similar or identical to ours, and our ability to commercialize any product candidates
we may develop, and our technology may be adversely affected.

Our success depends in large
part on our ability to obtain and maintain patents, trademarks and other intellectual property rights in the United States and other countries
with respect to our Alpha DaRT technology or other products or product candidates we may develop, their respective components, formulations,
combination therapies, methods used to manufacture them and methods of treatment and development that are important to our business, as
well as our ability to operate without infringing the proprietary rights of others. We rely on a combination of contractual provisions,
patent protection, as well as a combination of trade secret and trademark laws, to protect our core technology and commercial products
and prevent others from copying our treatment delivery devices and methods. However, these legal measures afford only limited protection,
and competitors or others may gain access to or use of our intellectual property and proprietary information. For example, patent protection
and intellectual property laws may not: (i) prevent competitors from obtaining access to our trade secrets, proprietary information, data,
know-how and technology; (ii) prevent others from copying our systems and methods; or (iii) provide a sustained competitive advantage.
If we do not adequately protect our intellectual property rights, competitors may be able to erode or negate any competitive advantage
we may have, which could harm our business and ability to achieve profitability.

To protect our proprietary
position, we file patent applications in the United States and abroad related to our